[225Ac]Ac-A9-0642 / Alpha-9 Oncology - LARVOL DELTA

A Phase 1/1b Study of GRPR‑Targeted Radioligand Therapy With [¹⁷⁷Lu] Lu‑A9‑0631 and [²²⁵Ac] Ac‑A9‑0642 in Patients With GRPR‑Positive Solid Tumors. (ESMO 2026) - No abstract available

Clinical • P1 data • Oncology • Solid Tumor

Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors (PRNewswire) - "The Phase 1 study is designed to assess the safety, tolerability, dosimetry, and recommended dose for expansion of 225Ac-A9-0642 and 177Lu-A9-0631 in patients with GRPR-positive advanced or metastatic tumors. Alpha-9 will utilize its proprietary GRPR imaging compound, 68Ga-A9-6217, for patient selection. Data is expected in late 2027."

P1 data • Trial status • Solid Tumor